De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial
| Autor: | Chen, Xiu-Chun a, Jiao, De-Chuang a, Qiao, Jiang-Hua a, Wang, Cheng-Zheng a, Sun, Xian-Fu a, Lu, Zhen-Duo a, Li, Lian-Fang a, Zhang, Chong-Jian a, Yan, Min a, Wei, Ya b, Chen, Bo c, Feng, Yue-Qing d, Deng, Miao e, Ma, Ming-De f, Plichta, Jennifer K g, He, You-Wen h, Liu, Zhen-Zhen a, * |
|---|---|
| Zdroj: | In The Lancet Oncology January 2025 26(1):27-36 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|